Trial · NCT01706926
Results by group265
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 265
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Placebo | Baseline (n=81, 81, 85, 79) | 5.78 | Standard Error 0.090 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Mavrilimumab 30 mg | Baseline (n=81, 81, 85, 79) | 5.73 | Standard Error 0.104 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Mavrilimumab 100 mg | Baseline (n=81, 81, 85, 79) | 5.91 | Standard Error 0.096 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Mavrilimumab 150 mg | Baseline (n=81, 81, 85, 79) | 5.67 | Standard Error 0.086 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Placebo | Change at Day 85 (n=77, 76, 79, 78) | -0.68 | Standard Error 0.136 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Mavrilimumab 30 mg | Change at Day 85 (n=77, 76, 79, 78) | -1.37 | Standard Error 0.136 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Mavrilimumab 100 mg | Change at Day 85 (n=77, 76, 79, 78) | -1.64 | Standard Error 0.132 | units on a scale |
| Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 | Mavrilimumab 150 mg | Change at Day 85 (n=77, 76, 79, 78) | -1.90 | Standard Error 0.136 | units on a scale |
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 | Placebo | 24.7 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 | Mavrilimumab 30 mg | 50.6 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 | Mavrilimumab 100 mg | 61.2 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 | Mavrilimumab 150 mg | 73.4 | percentage of participants | ||
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Placebo | TEAEs | 46.9 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 30 mg | TEAEs | 50.6 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | TEAEs | 42.4 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 150 mg | TEAEs | 54.4 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Placebo | TESAEs | 1.2 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 30 mg | TESAEs | 4.9 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | TESAEs | 5.9 | percentage of participants | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 150 mg | TESAEs | 2.5 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01706926/results